GFL Environmental announces successful completion of refinancing initiatives

PR Newswire

VAUGHAN, ON, Nov. 25, 2020 /PRNewswire/ – GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) (“GFL” or the “Company”) today provided an update on its recently announced refinancing initiatives.

On November 23, 2020, GFL closed its previously announced upsized offering of US$500.0 million in aggregate principal amount of 4.000% senior notes due 2028 issued at 99.171%. The Company will use the net proceeds from the offering to redeem all of its outstanding US$405.0 million aggregate principal amount of 7.000% Senior Notes due 2026 (the “7.000% Unsecured Notes”) and to pay related fees, premiums and accrued and unpaid interest on the 7.000% Unsecured Notes. The 7.000% Unsecured Notes will be redeemed in full on November 27, 2020.   Any remaining proceeds from the offering will be used to repay borrowings under the Company’s revolving credit facility.

GFL also completed the previously announced amendment to its revolving credit agreement to, among other things, (a) reduce the currently applicable margin by 50 basis points to 2.25% above Bankers Acceptance or Libor, (b) extend the maturity date to November 24, 2024, and (c) conform certain terms of the agreement to its other long term debt arrangements.  The amendment took effect on November 24, 2020.

“We are extremely proud of the results of our recent efforts to de-lever our balance sheet as well as having a continued focus on reducing our cost of capital to increase our free cash flow,” said Patrick Dovigi, Founder and Chief Executive Officer of GFL. “As I have said in the past, we have a very supportive group of institutional debt investors that have been in our capital structure for several years. We have worked very hard to build their trust as stewards of their capital and in turn they have supported us in our growth strategies, allowing us to continue to pursue our goal of creating long-term value for all of our stakeholders.”

About GFL

GFL, headquartered in Vaughan, Ontario, is the fourth largest diversified environmental services company in North America, providing a comprehensive line of non-hazardous solid waste management, infrastructure & soil remediation and liquid waste management services through its platform of facilities throughout Canada and in 27 states in the United States. Across its organization, GFL has a workforce of more than 13,000 employees and provides its broad range of environmental services to more than 135,000 commercial and industrial customers and its solid waste collection services to more than 4 million households.

Forward-Looking Information

This release includes certain “forward-looking statements”, including statements relating to the use of proceeds of the recently completed note offering. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by GFL as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the “Risk Factors” section of the Company’s final prospectus relating to its initial public offering dated March 2, 2020 and the Company’s other periodic filings with the SEC and the securities commissions or similar regulatory authorities in Canada. These factors are not intended to represent a complete list of the factors that could affect GFL. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. GFL undertakes no obligation to publicly update any forward-looking statement, except as required by applicable securities laws.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/gfl-environmental-announces-successful-completion-of-refinancing-initiatives-301180533.html

SOURCE GFL Environmental Inc.

LabCorp Is Scheduled to Present at The 2020 Evercore ISI 3rd Annual HealthCONx Conference

LabCorp Is Scheduled to Present at The 2020 Evercore ISI 3rd Annual HealthCONx Conference

BURLINGTON, N.C.–(BUSINESS WIRE)–
LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that members of the executive management team will participate in a virtual fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 3 at 1:50 p.m. ET.

A live webcast of the presentation will be available via the company website at www.LabCorp.com and archived for replay.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s drug development business, Covance, visit www.Covance.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to the impact of various factors on operating and financial results and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the impact of the COVID-19 pandemic on our business and financial condition as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, changes in business conditions and the economy in general, adverse weather conditions, the number of revenue days in a financial period, employee relations, personnel costs, and effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

# # #

LabCorp Contacts:

Investors: Clarissa Willett – 336-436-5076

[email protected]

Media: Christopher Allman-Bradshaw – 336-436-8263

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: General Health Hospitals Health Pharmaceutical Medical Supplies

MEDIA:

Logo
Logo

UnitedHealth Group to Host 2020 Investor Conference

UnitedHealth Group to Host 2020 Investor Conference

MINNETONKA, Minn.–(BUSINESS WIRE)–
UnitedHealth Group (NYSE: UNH) will host its annual Investor Conference with analysts and institutional investors virtually on Tuesday, December 1, 2020, beginning at 9:00 a.m. ET. Senior leaders will discuss how the Company is leading in the development of the next generation health system, advancing health care quality and outcomes for people, improving patient and physician experiences and working to reduce the total cost of health care. Management will also provide an overview of the Company’s outlook for its growth priorities and performance for 2021. In conjunction with the Investor Conference, an updated view of financial performance for 2020 and the initial outlook for 2021 will be released on the morning of Tuesday, December 1st at approximately 6:30 a.m. ET.

The Company will stream the presentations and management question and answer portion of this meeting and will make conference materials available on its Investor Relations page at www.unitedhealthgroup.com. A replay of the conference will be available on the Company web site.

About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at www.unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Contacts:

Brett Manderfeld

Senior Vice President

952-936-7216

Media:

Matt Stearns

Senior Vice President

202-276-0085

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Professional Services Health Hospitals Insurance Other Health General Health

MEDIA:

Logo
Logo

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Option granted to European Commission to purchase up to an additional 80 million doses

Agreement reflects Moderna’s commitment to make its vaccine available in multiple countries

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of the European Commission’s goal to secure access to a safe and effective COVID-19 vaccine for Europe.

Under the terms of the proposed agreement, the European Commission has the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses. The agreement will be finalized following a brief review period by the European Union Member States. This announcement follows the conclusion of advanced exploratory talks with the European Commission that began on August 24, 2020. Delivery of the vaccine could begin as early as the first quarter 2021 if it is approved for use by the European Medicines Agency (EMA) human medicines committee (CHMP), which started a rolling review of mRNA-1273 on November 17.

“We appreciate the confidence the European Commission has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines. We recognize that tackling this global pandemic will require a number of solutions, and we are proud of the role Moderna has been able to play in this global effort,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We have scaled up our manufacturing capacity outside of the United States with our strategic partners, Lonza and Rovi, to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021, if approved.”

In Europe, Moderna is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021. If the relevant regulatory approvals are granted, Moderna expects to begin shipping mRNA-1273 to the European Union beginning in December 2020.

On November 16, Moderna announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the terms of the Company’s anticipated sale of mRNA-1273 to the European Commission and European Union Member States; the anticipated finalization of the agreement for such sale; the timing for the delivery of mRNA-1273 to the European Commission; plans to submit a single marketing application to the EMA for mRNA-1273; the potential for mRNA-1273 to be marketed in EU member states and other countries; mRNA-1273’s efficacy and its ability to prevent infection or mitigate symptoms of COVID-19; and plans for the manufacture of mRNA-1273 and the scale of anticipated production. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no commercial product using mRNA technology has been approved and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having ongoing interactions with the FDA, EMA or other regulatory agencies, the FDA, EMA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Moderna

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

[email protected]

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Deere Reports Net Income of $757 Million for Fourth Quarter, $2.751 Billion for Year

PR Newswire

MOLINE, Ill., Nov. 25, 2020 /PRNewswire/ —

  • Fourth-quarter net income rises 5% aided by strong execution and disciplined cost management.
  • Improving fundamentals in agricultural sector setting stage for stronger demand in year ahead.
  • Earnings for 2021 forecast to be $3.6 to $4.0 billion.

Deere & Company (NYSE: DE) reported net income of $757 million for the fourth quarter ended November 1, 2020, or $2.39 per share, compared with net income of $722 million, or $2.27 per share, for the quarter ended November 3, 2019. For fiscal 2020, net income attributable to Deere & Company was $2.751 billion, or $8.69 per share, compared with $3.253 billion, or $10.15 per share, in 2019.

Worldwide net sales and revenues decreased 2 percent, to $9.731 billion, for the fourth quarter of 2020 and declined 9 percent, to $35.540 billion, for the full year. Equipment operations net sales were $8.659 billion for the quarter and $31.272 billion for the year, compared with corresponding totals of $8.703 billion and $34.886 billion in 2019.

“John Deere delivered another quarter of strong performance and a solid year despite the challenges associated with managing the pandemic,” said John C. May, chairman and chief executive officer. “In this regard, I would like to pay tribute to the thousands of John Deere employees, dealers and suppliers throughout the world who have helped us safely maintain our operations and serve customers. Because of their contributions, Deere was able to complete a successful year and is positioned to continue providing differentiated solutions and unlocking even greater value for customers.”


Company Outlook & Summary

Net income attributable to Deere & Company for fiscal 2021 is forecast to be in a range of $3.6 billion to $4.0 billion.

In the year ahead, Deere expects to benefit from improving conditions in the farm economy and stabilization in construction and forestry markets, according to May. “Higher crop prices and improved fundamentals are leading to renewed optimism in the agricultural sector and improving demand for farm equipment,” he said. “At the same time, we are looking forward to realizing the benefits of our smart industrial operating strategy, which is designed to accelerate the delivery of solutions that will drive improved profitability and sustainability in our customers’ operations.”


Deere & Company

Fourth Quarter

Full Year


$ in millions

2020

2019

% Change

2020

2019

% Change

Net sales and revenues

$

9,731

$

9,896

-2%

$

35,540

$

39,258

-9%

Net income

$

757

$

722

5%

$

2,751

$

3,253

-15%

Fully diluted EPS

$

2.39

$

2.27

$

8.69

$

10.15

Net income in the fourth quarter and full-year 2020 was negatively affected by impairment charges and employee-separation costs of $211 million and $458 million after-tax, respectively. For the same periods in 2019, the similar charges were $74 million and $82 million. In addition, net income was unfavorably affected by discrete adjustments to the provision for income taxes in both periods of 2020 and favorably impacted in both periods of 2019.


Equipment Operations

Fourth Quarter


$ in millions

2020

2019

% Change

Net sales

$

8,659

$

8,703

-1%

Operating profit

$

1,056

$

788

34%

Net income*

$

571

$

632

-10%

* Includes equity in income (loss) of unconsolidated affiliates.

For a discussion of net sales and operating profit results, see the Agriculture & Turf and Construction & Forestry sections below.


Agriculture & Turf

Fourth Quarter


$ in millions

2020

2019

% Change

Net sales

$

6,198

$

5,756

8%

Operating profit

$

860

$

527

63%

Operating margin

13.9%

9.2%

Agriculture & Turf sales increased for the quarter due to price realization and higher shipment volumes, partially offset by the unfavorable effects of currency translation. Operating profit rose primarily due to price realization, lower research and development expenses, reduced selling, administrative, and general expenses, improved shipment volumes / mix, and lower warranty expenses. These items were partially offset by employee-separation expenses and impairments.

 


Construction & Forestry

Fourth Quarter


$ in millions

2020

2019

% Change

Net sales

$

2,461

$

2,947

-16%

Operating profit

$

196

$

261

-25%

Operating margin

8.0%

8.9%

Construction & Forestry sales moved lower for the quarter primarily due to lower shipment volumes, partially offset by price realization. Operating profit declined mainly due to lower sales volume / mix, impairments, and employee-separation expenses. The decrease in profit was partially offset by price realization, lower research and development expenses, reduced selling, administrative, and general expenses, lower warranty expenses, and improved production costs.

 


Financial Services

Fourth Quarter


$ in millions

2020

2019

% Change

Net income

$

186

$

90

107%

The increase in financial services net income for the quarter was mainly due to lower impairments and reduced losses on operating-lease residual values and favorable financing spreads, partially offset by a higher provision for credit losses, and employee-separation expenses.


Market Conditions and Outlook (Annual)

Currency

Price


$ in millions

Net Sales

Translation

Realization

Agriculture & Turf

10% to 15%

1%

3%

Construction & Forestry

5% to 10%

1%

1%

John Deere Financial

Net Income

$630


Market Conditions & Outlook

Agriculture & Turf. Deere’s worldwide sales of agriculture and turf equipment are forecast to increase by 10 to 15 percent for fiscal-year 2021, including a positive currency-translation effect of 1 percent. Industry sales of agricultural equipment in the U.S. and Canada are forecast to rise 5 to 10 percent driven by gains in larger models. Full-year industry sales in the EU28 member nations are forecast to be flat to up 5%. In South America, industry sales of tractors and combines are forecast to be up about 5 percent while Asian sales are expected to be slightly lower. Industry sales of turf and utility equipment in the U.S. and Canada are forecast to be flat to up 5 percent.

Construction & Forestry. Deere’s worldwide sales of construction and forestry equipment are anticipated to be up 5 to 10 percent for 2021 with foreign-currency rates having a favorable translation effect of 1 percent. The outlook reflects some degree of recovery from the pandemic in construction equipment, continued strength in compact construction due to residential building activity, and expected growth in the roadbuilding sector. On an industry basis, North American construction equipment sales are expected to be down about 5 percent with sales of compact equipment up about 5 percent. Global forestry industry sales are forecast to be flat to up 5 percent for the year.

Financial Services. Fiscal-year 2021 net income attributable to Deere & Company for the financial services operations is forecast to be approximately $630 million. Results are expected to benefit from favorable financing spreads, lower losses on operating-lease residual values, and income earned on a higher average portfolio, partially offset by a higher provision for credit losses.

John Deere Capital Corporation

The following is disclosed on behalf of the company’s financial services subsidiary, John Deere Capital Corporation (JDCC), in connection with the disclosure requirements applicable to its periodic issuance of debt securities in the public market.

Fourth Quarter

Full Year


$ in millions

2020

2019

% Change

2020

2019

% Change

Revenue

$

693

$

785

-12%

$

2,808

$

2,890

-3%

Net income

$

154

$

68

126%

$

425

$

419

1%

Ending portfolio balance

$

38,726

$

38,251

1%

Net income for the current quarter was higher than in the fourth quarter of 2019 primarily due to lower impairments and reduced losses on operating-lease residual values, favorable financing spreads, and a lower provision for credit losses, partially offset by employee-separation expenses. Full year 2020 net income was about the same as in 2019 with lower impairments and reduced losses on operating-lease residual values, and income from a higher average portfolio, largely offset by a higher provision for credit losses and unfavorable financing spreads. The full year 2019 was also affected by favorable discrete adjustments to the provision for income taxes.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  Statements under “Company Outlook & Summary,” “Market Conditions & Outlook,” and other forward-looking statements herein that relate to future events, expectations, and trends involve factors that are subject to change, and risks and uncertainties that could cause actual results to differ materially.  Some of these risks and uncertainties could affect particular lines of business, while others could affect all of the company’s businesses.

The company’s agricultural equipment business is subject to a number of uncertainties including the factors that affect farmers’ confidence and financial condition.  These factors include demand for agricultural products, world grain stocks, weather conditions, soil conditions, harvest yields, prices for commodities and livestock, crop and livestock production expenses, availability of transport for crops, trade restrictions and tariffs (e.g., China), global trade agreements, the level of farm product exports (including concerns about genetically modified organisms), the growth and sustainability of non-food uses for some crops (including ethanol and biodiesel production), real estate values, available acreage for farming, the land ownership policies of governments, changes in government farm programs and policies, international reaction to such programs, changes in and effects of crop insurance programs, changes in environmental regulations and their impact on farming practices, animal diseases (e.g., African swine fever) and their effects on poultry, beef and pork consumption and prices and on livestock feed demand, and crop pests and diseases and the impact of the COVID pandemic on the agricultural industry including demand for, and production and exports of, agricultural products, and commodity prices.

Factors affecting the outlook for the company’s turf and utility equipment include consumer confidence, weather conditions, customer profitability, labor supply, consumer borrowing patterns, consumer purchasing preferences, housing starts and supply, infrastructure investment, spending by municipalities and golf courses, and consumable input costs.  Many of these factors have been and may continue to be impacted by global economic effects, including the downturn resulting from the COVID pandemic and responses to the pandemic taken by governments and other authorities.

Consumer spending patterns, real estate and housing prices, the number of housing starts, interest rates, commodity prices such as oil and gas, the levels of public and non-residential construction, and investment in infrastructure are important to sales and results of the company’s construction and forestry equipment.  Prices for pulp, paper, lumber and structural panels are important to sales of forestry equipment.  Many of these factors affecting the outlook for the company’s construction and forestry equipment have been and may continue to be impacted by global economic effects, including the downturn resulting from the COVID pandemic and responses to the pandemic taken by governments and other authorities.

All of the company’s businesses and its results are affected by general economic conditions in the global markets and industries in which the company operates; customer confidence in general economic conditions; government spending and taxing; foreign currency exchange rates and their volatility, especially fluctuations in the value of the U.S. dollar; interest rates (including the availability of IBOR reference rates); inflation and deflation rates; changes in weather patterns; the political and social stability of the global markets in which the company operates; the effects of, or response to, terrorism and security threats; wars and other conflicts; natural disasters; and the spread of major epidemics (including the COVID pandemic) and government and industry responses to epidemics such as travel restrictions and extended shut down of businesses.

Uncertainties related to the magnitude and duration of the COVID pandemic may significantly adversely affect the company’s business and outlook.  These uncertainties include: prolonged reduction or closure of the company’s operations, or a delayed recovery in our operations; additional closures as mandated or otherwise made necessary by governmental authorities; disruptions in the supply chain and a prolonged delay in resumption of operations by one or more key suppliers, or the failure of any key suppliers; the company’s ability to meet commitments to customers on a timely basis as a result of increased costs and supply challenges; the ability to receive goods on a timely basis and at anticipated costs; increased logistics costs; delays in the company’s strategic initiatives as a result of reduced spending on research and development; additional operating costs at facilities that remain open due to remote working arrangements, adherence to social distancing guidelines and other COVID-related challenges; increased risk of cyber attacks on network connections used in remote working arrangements; increased privacy-related risks due to processing health-related personal information; legal claims related to personal protective equipment designed, made, or provided by the company or alleged exposure to COVID on company premises; absence of employees due to illness; the impact of the pandemic on the company’s customers and dealers, and their delays in their plans to invest in new equipment; requests by the company’s customers or dealers for payment deferrals and contract modifications; the impact of disruptions in the global capital markets and/or continued declines in the company’s financial performance, outlook or credit ratings, which could impact the company’s ability to obtain funding in the future; the duration and impact of the resurgence in COVID cases in any country, state, or region; and the impact of the pandemic on demand for our products and services as discussed above.  It is unclear when a sustained economic recovery could occur and what a recovery may look like.  All of these factors could materially and adversely affect our business, liquidity, results of operations and financial position.

Significant changes in market liquidity conditions, changes in the company’s credit ratings and any failure to comply with financial covenants in credit agreements could impact access to funding and funding costs, which could reduce the company’s earnings and cash flows.  Financial market conditions could also negatively impact customer access to capital for purchases of the company’s products and customer confidence and purchase decisions, borrowing and repayment practices, and the number and size of customer loan delinquencies and defaults.  A debt crisis, in Europe or elsewhere, could negatively impact currencies, global financial markets, social and political stability, funding sources and costs, asset and obligation values, customers, suppliers, demand for equipment, and company operations and results.  The company’s investment management activities could be impaired by changes in the equity, bond and other financial markets, which would negatively affect earnings.

The withdrawal of the United Kingdom from the European Union and the perceptions as to the impact of the withdrawal may adversely affect business activity, political stability and economic conditions in the United Kingdom, the European Union and elsewhere.  The economic conditions and outlook could be further adversely affected by (i) uncertainty regarding any new or modified trade arrangements between the United Kingdom and the European Union and/or other countries, (ii) the risk that one or more other European Union countries could come under increasing pressure to leave the European Union, or (iii) the risk that the euro as the single currency of the Eurozone could cease to exist.  Any of these developments, or the perception that any of these developments are likely to occur, could affect economic growth or business activity in the United Kingdom or the European Union, and could result in the relocation of businesses, cause business interruptions, lead to economic recession or depression, and impact the stability of the financial markets, availability of credit, currency exchange rates, interest rates, financial institutions, and political, financial and monetary systems.  Any of these developments could affect our businesses, liquidity, results of operations and financial position.

Additional factors that could materially affect the company’s operations, access to capital, expenses and results include changes in, uncertainty surrounding and the impact of governmental trade, banking, monetary and fiscal policies, including financial regulatory reform and its effects on the consumer finance industry, derivatives, funding costs and other areas; governmental programs, policies, and tariffs for the benefit of certain industries or sectors; sanctions in particular jurisdictions; retaliatory actions to such changes in trade, banking, monetary and fiscal policies; actions by central banks; actions by financial and securities regulators; actions by environmental, health and safety regulatory agencies, including those related to engine emissions, carbon and other greenhouse gas emissions, noise and the effects of climate change; changes to GPS radio frequency bands or their permitted uses; changes in labor and immigration regulations; changes to accounting standards; changes in tax rates, estimates, laws and regulations and company actions related thereto; changes to and compliance with privacy regulations; changes to and compliance with economic sanctions and export controls laws and regulations; compliance with U.S. and foreign laws when expanding to new markets and otherwise; and actions by other regulatory bodies.

Other factors that could materially affect results include production, design and technological innovations and difficulties, including capacity and supply constraints and prices; the loss of or challenges to intellectual property rights whether through theft, infringement, counterfeiting or otherwise; the availability and prices of strategically sourced materials, components and whole goods; delays or disruptions in the company’s supply chain or the loss of liquidity by suppliers; disruptions of infrastructures that support communications, operations or distribution; the failure of customers, dealers, suppliers or the company to comply with laws, regulations and company policy pertaining to employment, human rights, health, safety, the environment, sanctions, export controls, anti-corruption, privacy and data protection and other ethical business practices; events that damage the company’s reputation or brand; significant investigations, claims, lawsuits or other legal proceedings; start-up of new plants and products; the success of new product initiatives; changes in customer product preferences and sales mix; gaps or limitations in rural broadband coverage, capacity and speed needed to support technology solutions; oil and energy prices, supplies and volatility; the availability and cost of freight; actions of competitors in the various industries in which the company competes, particularly price discounting; dealer practices especially as to levels of new and used field inventories; changes in demand and pricing for used equipment and resulting impacts on lease residual values; labor relations and contracts; changes in the ability to attract, train and retain qualified personnel; acquisitions and divestitures of businesses; greater than anticipated transaction costs; the integration of new businesses; the failure or delay in closing or realizing anticipated benefits of acquisitions, joint ventures or divestitures; the implementation of organizational changes; the failure to realize anticipated savings or benefits of cost reduction, productivity, or efficiency efforts; difficulties related to the conversion and implementation of enterprise resource planning systems; security breaches, cybersecurity attacks, technology failures and other disruptions to the company’s and suppliers’ information technology infrastructure; changes in company declared dividends and common stock issuances and repurchases; changes in the level and funding of employee retirement benefits; changes in market values of investment assets, compensation, retirement, discount and mortality rates which impact retirement benefit costs; and significant changes in health care costs.

The liquidity and ongoing profitability of John Deere Capital Corporation and other credit subsidiaries depend largely on timely access to capital in order to meet future cash flow requirements, and to fund operations, costs, and purchases of the company’s products.  If general economic conditions deteriorate or capital markets become more volatile, including as a result of the COVID pandemic, funding could be unavailable or insufficient.  Additionally, customer confidence levels may result in declines in credit applications and increases in delinquencies and default rates, which could materially impact write-offs and provisions for credit losses.

The company’s forward-looking statements are based upon assumptions relating to the factors described above, which are sometimes based upon estimates and data prepared by government agencies.  Such estimates and data are often revised.  The company, except as required by law, undertakes no obligation to update or revise its forward-looking statements, whether as a result of new developments or otherwise.  Further information concerning the company and its businesses, including factors that could materially affect the company’s financial results, is included in the company’s other filings with the SEC (including, but not limited to, the factors discussed in Item 1A. Risk Factors of the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q).

 

 


Fourth Quarter 2020 Press Release

(in millions of dollars)

Unaudited

Three Months Ended

Twelve Months Ended

November 1

November 3

%

November 1

November 3

%

2020

2019

Change

2020

2019

Change

Net sales and revenues:

Agriculture and turf

$

6,198

$

5,756

+8

$

22,325

$

23,666

-6

Construction and forestry

2,461

2,947

-16

8,947

11,220

-20

Total net sales

8,659

8,703

-1

31,272

34,886

-10

Financial services

891

971

-8

3,589

3,621

-1

Other revenues

181

222

-18

679

751

-10

Total net sales and revenues

$

9,731

$

9,896

-2

$

35,540

$

39,258

-9

Operating profit: *

Agriculture and turf

$

860

$

527

+63

$

2,969

$

2,506

+18

Construction and forestry

196

261

-25

590

1,215

-51

Financial services

249

128

+95

746

694

+7

Total operating profit

1,305

916

+42

4,305

4,415

-2

Reconciling items **

(219)

(90)

+143

(472)

(310)

+52

Income taxes

(329)

(104)

+216

(1,082)

(852)

+27

Net income attributable to Deere & Company

$

757

$

722

+5

$

2,751

$

3,253

-15

* Operating profit is income from continuing operations before corporate expenses, certain external interest expense, certain foreign exchange gains and losses, and income taxes. Operating profit of the financial services segment includes the effect of interest expense and foreign exchange gains or losses.

** Reconciling items are primarily corporate expenses, certain external interest expense, certain foreign exchange gains and losses, pension and postretirement benefit costs excluding the service cost component, and net income attributable to noncontrolling interests.

 

 

DEERE & COMPANY

STATEMENT OF CONSOLIDATED INCOME

For the Three Months Ended November 1, 2020 and November 3, 2019

(In millions of dollars and shares except per share amounts) Unaudited 

2020

2019


Net Sales and Revenues

Net sales

$

8,659

$

8,703

Finance and interest income

867

956

Other income

205

237

Total

9,731

9,896


Costs and Expenses

Cost of sales

6,470

6,735

Research and development expenses

443

488

Selling, administrative and general expenses

1,011

945

Interest expense

278

388

Other operating expenses

414

515

Total

8,616

9,071


Income of Consolidated Group before Income Taxes

1,115

825

Provision for income taxes

329

104


Income of Consolidated Group

786

721

Equity in income (loss) of unconsolidated affiliates

(28)

1


Net Income

758

722

Less: Net income attributable to noncontrolling interests

1


Net Income Attributable to Deere & Company

$

757

$

722


Per Share Data

Basic

$

2.41

$

2.30

Diluted

$

2.39

$

2.27


Average Shares Outstanding

Basic

314.1

313.9

Diluted

317.1

317.9

See Condensed Notes to Consolidated Financial Statements.

 

 

DEERE & COMPANY

STATEMENT OF CONSOLIDATED INCOME

For the Years Ended November 1, 2020 and November 3, 2019

(In millions of dollars and shares except per share amounts) Unaudited

2020

2019


Net Sales and Revenues

Net sales

$

31,272

$

34,886

Finance and interest income

3,450

3,493

Other income

818

879

Total

35,540

39,258


Costs and Expenses

Cost of sales

23,677

26,792

Research and development expenses

1,644

1,783

Selling, administrative and general expenses

3,477

3,551

Interest expense

1,247

1,466

Other operating expenses

1,612

1,578

Total

31,657

35,170


Income of Consolidated Group before Income Taxes

3,883

4,088

Provision for income taxes

1,082

852


Income of Consolidated Group

2,801

3,236

Equity in income (loss) of unconsolidated affiliates

(48)

21


Net Income

2,753

3,257

Less: Net income attributable to noncontrolling interests

2

4


Net Income Attributable to Deere & Company

$

2,751

$

3,253


Per Share Data

Basic

$

8.77

$

10.28

Diluted

$

8.69

$

10.15


Average Shares Outstanding

Basic

313.5

316.5

Diluted

316.6

320.6

See Condensed Notes to Consolidated Financial Statements.

 

 

DEERE & COMPANY

CONDENSED CONSOLIDATED BALANCE SHEET

As of November 1, 2020 and November 3, 2019

(In millions of dollars) Unaudited

2020

2019


Assets

Cash and cash equivalents

$

7,066

$

3,857

Marketable securities

641

581

Receivables from unconsolidated affiliates

31

46

Trade accounts and notes receivable – net

4,171

5,230

Financing receivables – net

29,750

29,195

Financing receivables securitized – net

4,703

4,383

Other receivables

1,220

1,487

Equipment on operating leases – net

7,298

7,567

Inventories

4,999

5,975

Property and equipment – net

5,817

5,973

Investments in unconsolidated affiliates

193

215

Goodwill

3,081

2,917

Other intangible assets – net

1,327

1,380

Retirement benefits

863

840

Deferred income taxes

1,499

1,466

Other assets

2,432

1,899


Total Assets

$

75,091

$

73,011


Liabilities and Stockholders’ Equity


Liabilities

Short-term borrowings

$

8,582

$

10,784

Short-term securitization borrowings

4,682

4,321

Payables to unconsolidated affiliates

105

142

Accounts payable and accrued expenses

10,112

9,656

Deferred income taxes

519

495

Long-term borrowings

32,734

30,229

Retirement benefits and other liabilities

5,413

5,953

Total liabilities

62,147

61,580

Redeemable noncontrolling interest

14


Stockholders’ Equity

Total Deere & Company stockholders’ equity

12,937

11,413

Noncontrolling interests

7

4

Total stockholders’ equity

12,944

11,417


Total Liabilities and Stockholders’ Equity

$

75,091

$

73,011

See Condensed Notes to Consolidated Financial Statements.

 

 

DEERE & COMPANY

STATEMENT OF CONSOLIDATED CASH FLOWS

For the Years Ended November 1, 2020 and November 3, 2019

(In millions of dollars) Unaudited

2020

2019


Cash Flows from Operating Activities

Net income

$

2,753

$

3,257

Adjustments to reconcile net income to net cash provided by operating activities:

Provision for credit losses

110

43

Provision for depreciation and amortization

2,118

2,019

Impairment charges

194

77

Share-based compensation expense

81

82

Loss on sales of businesses and unconsolidated affiliates

24

5

Undistributed earnings of unconsolidated affiliates

(7)

9

Credit for deferred income taxes

(11)

(465)

Changes in assets and liabilities:

Trade, notes, and financing receivables related to sales

2,009

(869)

Inventories

397

(780)

Accounts payable and accrued expenses

(7)

46

Accrued income taxes payable/receivable

8

173

Retirement benefits

(537)

(233)

Other

351

48

Net cash provided by operating activities

7,483

3,412


Cash Flows from Investing Activities

Collections of receivables (excluding receivables related to sales)

17,381

16,706

Proceeds from maturities and sales of marketable securities

93

89

Proceeds from sales of equipment on operating leases

1,783

1,648

Proceeds from sales of business and unconsolidated affiliates, net of cash sold

93

Cost of receivables acquired (excluding receivables related to sales)

(19,965)

(18,873)

Acquisitions of businesses, net of cash acquired

(66)

Purchases of marketable securities

(130)

(140)

Purchases of property and equipment

(820)

(1,120)

Cost of equipment on operating leases acquired

(1,836)

(2,329)

Collateral on derivatives – net

268

59

Other

(27)

(57)

Net cash used for investing activities

(3,319)

(3,924)


Cash Flows from Financing Activities

Decrease in total short-term borrowings

(1,360)

(917)

Proceeds from long-term borrowings

9,271

9,986

Payments of long-term borrowings

(7,383)

(6,426)

Proceeds from issuance of common stock

331

178

Repurchases of common stock

(750)

(1,253)

Dividends paid

(956)

(943)

Other

(133)

(116)

Net cash provided by (used for) financing activities

(980)

509


Effect of Exchange Rate Changes on Cash, Cash Equivalents, and Restricted Cash

32

(56)


Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash

3,216

(59)


Cash, Cash Equivalents, and Restricted Cash at Beginning of Year

3,956

4,015


Cash, Cash Equivalents, and Restricted Cash at End of Year

$

7,172

$

3,956

See Condensed Notes to Consolidated Financial Statements.


Condensed Notes to Consolidated Financial Statements (Unaudited)

(1)

In September 2020, the Company sold its German lawn mower business. At the time of the sale, total assets were $26 million, which were recorded in “Other assets” and total liabilities were $5 million, which were recorded in “Accounts payable and accrued expenses.” No cash proceeds were received, resulting in a loss on sale, including transaction costs, of $24 million pretax and after-tax. The loss was recorded with a $24 million pretax and after-tax accrual recognized in the third quarter of 2020 when a definitive sale agreement was finalized. The loss was recorded in “Other operating expenses” in the agriculture and turf operations.

(2)

In the fourth quarter and full year 2020, the Company recorded impairments and other charges as follows:

Three Months Ended November 1, 2020

Twelve Months Ended November 1, 2020

Agriculture

Construction

Financial

Agriculture

Construction

Financial

and Turf

and Forestry

Services

Total

and Turf

and Forestry

Services

Total


Factory closure

China – agriculture
equipment *

$

7

$

7

$

20

$

20


Fixed asset and lease
impairments

German asphalt plant
factory *

$

62

62

Brazil construction
equipment factory *

$

16

16

16

16

Other international
fixed assets ****

17

2

19

17

2

19

Equipment on operating
leases **

$

22

22

Operating lease
inventory **

10

10


Affiliate company
impairments

Minority investment in
construction equipment
company headquartered
in South Africa ***

23

23

43

43

Construction equipment
joint venture located in
Brazil ***

7

7

7

7

Total 1 2

$

24

$

48

$

72

$

37

$

130

$

32

$

199

*      Recorded in “Cost of sales”

**    Recorded in “Other operating expenses”

***  Recorded in “Equity in income (loss) of unconsolidated affiliate”

****Recorded $15 million in “Cost of sales” and $4 million in “Selling, administrative, and general expenses”

1      The after-tax effect was $62 million and $180 million in the fourth quarter and full year 2020, respectively.

2      The non-cash charges were $72 million and $194 million in the fourth quarter and full year 2020, respectively.

(3)

During first and fourth quarters of 2020, the Company implemented employee-separation programs for the Company’s salaried workforce in several geographic areas, including the United States, Europe, Asia, and Latin America. The programs’ main purpose was to improve efficiency through a leaner, more flexible organization. The programs were largely voluntary in nature with the expense recorded primarily in the period in which the employees irrevocably accepted a separation offer. For the limited involuntary employee-separation programs, the expense was recorded when management committed to a plan, the plan was communicated to the employees, and the employees were not required to provide service beyond the legal notification period. The programs provided for cash payments based on years of service, and in some countries, subsidized healthcare for a limited period and outplacement services. The total pretax expenses for the fourth quarter and full year of 2020 were as follows:

Three Months Ended November 1, 2020

Twelve Months Ended November 1, 2020

Agriculture

Construction

Financial

Agriculture

Construction

Financial

and Turf

and Forestry

Services

Total

and Turf

and Forestry

Services

Total

Cost of sales

$

50

$

13

$

63

$

82

$

22

$

104

Research and
   development expenses

32

5

37

47

8

55

Selling, administrative
   and general expenses

58

10

$

11

79

96

24

$

15

135

Other operating expenses

18

41

Total

$

140

$

28

$

11

$

197

$

225

$

54

$

15

$

335

Total program payments will be $301 million with $166 million paid in 2020 and $135 million to be disbursed over two years. Included in total pretax expense are non-cash charges of $13 million and $34 million in the fourth quarter and full year 2020, respectively, resulting from curtailment losses in certain OPEB plans that were recorded outside of operating profit in “Other operating expense.” Annual savings from these programs are estimated to be approximately $250 million, of which approximately $85 million was realized in 2020.

(4)

In September 2020, the Company acquired Unimil, a leading Brazilian Company in the after-sales service parts business for sugarcane harvesters, which is based in Piracicaba, Brazil. The total cash purchase price before final adjustments, net of cash acquired of $5 million, was $66 million with $6 million funded to an escrow account to secure certain indemnity obligations. In addition to the cash purchase price, $14 million of liabilities were assumed. The preliminary asset and liability fair values at the acquisition date assigned to the assets and liabilities were approximately $5 million of trade accounts receivables, $2 million of other receivables, $10 million of inventories, $22 million of property and equipment, $28 million of goodwill, $13 million of other intangible assets, $5 million of accounts payable and accrued expenses, and $9 million of net deferred tax liabilities. The goodwill is not expected to be deducted for tax purposes. Unimil is included in the Company’s agriculture and turf operating segment.

(5)

Dividends declared and paid on a per share basis were as follows:

Three Months Ended

Twelve Months Ended

November 1

November 3

November 1

November 3

2020

2019

2020

2019

Dividends declared

$

.76

$

.76

$

3.04

$

3.04

Dividends paid

$

.76

$

.76

$

3.04

$

2.97

(6)

The calculation of basic net income per share is based on the average number of shares outstanding. The calculation of diluted net income per share recognizes any dilutive effect of share-based compensation.

(7)

The consolidated financial statements represent the consolidation of all Deere & Company’s subsidiaries. In the supplemental consolidating data in Note 8 to the financial statements, the “Equipment Operations” represents the enterprise without “Financial Services”, which include the Company’s agriculture and turf operations and construction and forestry operations, and other corporate assets, liabilities, revenues, and expenses not reflected  within “Financial Services”.

 

 

(8) SUPPLEMENTAL CONSOLIDATING DATA

STATEMENT OF INCOME

For the Three Months Ended November 1, 2020 and November 3, 2019 

(In millions of dollars) Unaudited

EQUIPMENT OPERATIONS 1

FINANCIAL SERVICES

ELIMINATIONS

CONSOLIDATED

2020

2019

2020

2019

2020

2019

2020

2019


Net Sales and Revenues

Net sales

$

8,659

$

8,703

$

8,659

$

8,703

Finance and interest income

38

40

$

891

$

1,007

$

(62)

$

(91)

867

956


 2

Other income

211

267

60

50

(66)

(80)

205

237


 3

Total

8,908

9,010

951

1,057

(128)

(171)

9,731

9,896


Costs and Expenses

Cost of sales

6,470

6,735

6,470

6,735

Research and development expenses

443

488

443

488

Selling, administrative and general
expenses

890

840

123

106

(2)

(1)

1,011

945


 4

Interest expense

92

75

195

323

(9)

(10)

278

388


 5

Interest compensation to Financial
Services

53

81

(53)

(81)


 5

Other operating expenses

93

96

385

498

(64)

(79)

414

515


 6

Total

8,041

8,315

703

927

(128)

(171)

8,616

9,071


Income before Income Taxes

867

695

248

130

1,115

825

Provision for income taxes

266

64

63

40

329

104


Income after Income Taxes

601

631

185

90

786

721

Equity in income (loss) of 
unconsolidated affiliates

(29)

1

1

(28)

1


Net Income

572

632

186

90

758

722

Less: Net income attributable to
noncontrolling interests

1

1


Net Income Attributable to
Deere & Company

$

571

$

632

$

186

$

90

$

757

$

722

The supplemental consolidating data is presented for informational purposes. Transactions between the “Equipment Operations” and “Financial Services” have been eliminated to arrive at the consolidated financial statements.


1 The Equipment Operations represents the enterprise without Financial Services. The Equipment Operations includes the Company’s agriculture and turf operations, construction and forestry operations, and other corporate assets, liabilities, revenues and expenses not reflected within Financial Services.


2 Elimination of Financial Services interest income earned from Equipment Operations.


3 Elimination of Equipment Operations’ margin from inventory transferred to equipment on operating leases.


4 Elimination of intercompany service fees.


5 Elimination of Equipment Operations interest expense to Financial Services.


6 Elimination of Financial Services lease depreciation expense related to inventory transferred to equipment on operating leases.

 

 

SUPPLEMENTAL CONSOLIDATING DATA (Continued)

STATEMENT OF INCOME

For the Years Ended November 1, 2020 and November 3, 2019 

(In millions of dollars) Unaudited

EQUIPMENT OPERATIONS 1

FINANCIAL SERVICES

ELIMINATIONS

CONSOLIDATED

2020

2019

2020

2019

2020

2019

2020

2019


Net Sales and Revenues

Net sales

$

31,272

$

34,886

$

31,272

$

34,886

Finance and interest income

112

118

$

3,610

$

3,735

$

(272)

$

(360)

3,450

3,493


 2

Other income

808

881

257

234

(247)

(236)

818

879


 3

Total

32,192

35,885

3,867

3,969

(519)

(596)

35,540

39,258


Costs and Expenses

Cost of sales

23,679

26,793

(2)

(1)

23,677

26,792


 4

Research and development expenses

1,644

1,783

1,644

1,783

Selling, administrative and general expenses

2,878

3,031

606

528

(7)

(8)

3,477

3,551


 4

Interest expense

329

256

942

1,234

(24)

(24)

1,247

1,466


 5

Interest compensation to Financial Services

248

336

(248)

(336)


 5

Other operating expenses

278

299

1,572

1,506

(238)

(227)

1,612

1,578


 6

Total

29,056

32,498

3,120

3,268

(519)

(596)

31,657

35,170


Income before Income Taxes

3,136

3,387

747

701

3,883

4,088

Provision for income taxes

899

689

183

163

1,082

852


Income after Income Taxes

2,237

2,698

564

538

2,801

3,236

Equity in income (loss) of 
unconsolidated affiliates

(50)

20

2

1

(48)

21


Net Income

2,187

2,718

566

539

2,753

3,257

Less: Net income attributable to noncontrolling interests

2

4

2

4


Net Income Attributable to
Deere & Company

$

2,185

$

2,714

$

566

$

539

$

2,751

$

3,253

The supplemental consolidating data is presented for informational purposes. Transactions between the “Equipment Operations” and “Financial Services” have been eliminated to arrive at the consolidated financial statements.


1 The Equipment Operations represents the enterprise without Financial Services. The Equipment Operations includes the Company’s agriculture and turf operations, construction and forestry operations, and other corporate assets, liabilities, revenues and expenses not reflected within Financial Services.


2 Elimination of Financial Services interest income earned from Equipment Operations.


3 Elimination of Equipment Operations’ margin from inventory transferred to equipment on operating leases.


4 Elimination of intercompany service fees.


5 Elimination of Equipment Operations interest expense to Financial Services.


6 Elimination of Financial Services lease depreciation expense related to inventory transferred to equipment on operating leases.

 

 

SUPPLEMENTAL CONSOLIDATING DATA (Continued)

CONDENSED BALANCE SHEET

As of November 1, 2020 and November 3, 2019

(In millions of dollars) Unaudited

EQUIPMENT
OPERATIONS 1

FINANCIAL
SERVICES

ELIMINATIONS

CONSOLIDATED

2020

2019

2020

2019

2020

2019

2020

2019


Assets

Cash and cash equivalents

$

6,145

$

3,175

$

921

$

682

$

7,066

$

3,857

Marketable securities

7

1

634

580

641

581

Receivables from unconsolidated
affiliates

5,290

2,017

$

(5,259)

$

(1,971)

31

46


 7

Trade accounts and notes receivable
– net

1,013

1,482

4,238

5,153

(1,080)

(1,405)

4,171

5,230


 8

Financing receivables – net

106

65

29,644

29,130

29,750

29,195

Financing receivables securitized –
net

26

44

4,677

4,339

4,703

4,383

Other receivables

1,117

1,376

151

116

(48)

(5)

1,220

1,487


 8

Equipment on operating leases – net

7,298

7,567

7,298

7,567

Inventories

4,999

5,975

4,999

5,975

Property and equipment – net

5,778

5,929

39

44

5,817

5,973

Investments in unconsolidated
affiliates

174

199

19

16

193

215

Goodwill

3,081

2,917

3,081

2,917

Other intangible assets – net

1,327

1,380

1,327

1,380

Retirement benefits

859

836

59

58

(55)

(54)

863

840


 9

Deferred income taxes

1,763

1,896

45

57

(309)

(487)

1,499

1,466


 10

Other assets

1,439

1,158

994

741

(1)

2,432

1,899


Total Assets

$

33,124

$

28,450

$

48,719

$

48,483

$

(6,752)

$

(3,922)

$

75,091

$

73,011


Liabilities and Stockholders’
Equity


Liabilities

Short-term borrowings

$

292

$

987

$

8,290

$

9,797

$

8,582

$

10,784

Short-term securitization borrowings

26

44

4,656

4,277

4,682

4,321

Payables to unconsolidated affiliates

104

142

5,260

1,970

$

(5,259)

$

(1,970)

105

142


 7

Accounts payable and accrued expenses

9,114

9,232

2,127

1,836

(1,129)

(1,412)

10,112

9,656


 8

Deferred income taxes

385

414

443

568

(309)

(487)

519

495


 10

Long-term borrowings

10,124

5,415

22,610

24,814

32,734

30,229

Retirement benefits and other liabilities

5,366

5,912

102

94

(55)

(53)

5,413

5,953


 9

Total liabilities

25,411

22,146

43,488

43,356

(6,752)

(3,922)

62,147

61,580

Redeemable noncontrolling interest

14

14


Stockholders’ Equity

Total Deere & Company stockholders’
equity

12,937

11,413

5,231

5,127

(5,231)

(5,127)

12,937

11,413


 11

Noncontrolling interests

7

4

7

4

Financial Services equity

(5,231)

(5,127)

5,231

5,127


 11

Adjusted total stockholders’ equity

7,713

6,290

5,231

5,127

12,944

11,417


Total Liabilities and Stockholders’
Equity

$

33,124

$

28,450

$

48,719

$

48,483

$

(6,752)

$

(3,922)

$

75,091

$

73,011

The supplemental consolidating data is presented for informational purposes. Transactions between the “Equipment Operations” and “Financial Services” have been eliminated to arrive at the consolidated financial statements.


1  The Equipment Operations represents the enterprise without Financial Services. The Equipment Operations includes the Company’s agriculture and turf operations, construction and forestry operations, and other corporate assets, liabilities, revenues and expenses not reflected within Financial Services.


7  Elimination of receivables / payables between Equipment Operations and Financial Services.


8  Reclassification of sales incentive accruals on receivables sold to Financial Services.


9  Reclassification of net pension assets / liabilities.


10 Reclassification of deferred tax assets / liabilities in the same taxing jurisdictions.


11 Elimination of Financial Services equity.

 

 

SUPPLEMENTAL CONSOLIDATING DATA (Continued)

STATEMENT OF CASH FLOWS

For the Years Ended November 1, 2020 and November 3, 2019

(In millions of dollars) Unaudited

EQUIPMENT
OPERATIONS 1

FINANCIAL
SERVICES

ELIMINATIONS

CONSOLIDATED

2020

2019

2020

2019

2020

2019

2020

2019


Cash Flows from Operating Activities

Net income

$

2,187

$

2,718

$

566

$

539

$

2,753

$

3,257

Adjustments to reconcile net income to net cash
provided by operating activities:

Provision for credit losses

5

14

105

29

110

43

Provision for depreciation and amortization

1,016

1,015

1,227

1,135

$

(125)

$

(131)

2,118

2,019


 12

Impairment charges

162

32

77

194

77

Share-based compensation expense

81

82

81

82


 13

Loss on sale of businesses and unconsolidated
affiliates

24

5

24

5

Undistributed earnings of unconsolidated
affiliates

381

437

(2)

(2)

(386)

(426)

(7)

9


 14

Provision (credit) for deferred income taxes

105

(222)

(116)

(243)

(11)

(465)

Changes in assets and liabilities:

Trade, notes, and financing receivables related
to sales

373

(142)

1,636

(727)

2,009

(869)


15, 17, 18

Inventories

1,011

(102)

(614)

(678)

397

(780)


 16

Accounts payable and accrued expenses

(331)

13

(1)

163

325

(130)

(7)

46


 17

Accrued income taxes payable/receivable

(14)

(355)

22

528

8

173

Retirement benefits

(544)

(235)

7

2

(537)

(233)

Other

385

54

136

190

(170)

(196)

351

48


12, 13, 16

Net cash provided by operating activities

4,760

3,200

1,976

2,418

747

(2,206)

7,483

3,412


Cash Flows from Investing Activities

Collections of receivables (excluding receivables
related to sales)

18,829

18,190

(1,448)

(1,484)

17,381

16,706


 15

Proceeds from maturities and sales of marketable
securities

12

93

77

93

89

Proceeds from sales of equipment on operating
leases

1,783

1,648

1,783

1,648

Proceeds from sales of businesses and
unconsolidated affiliates, net of cash sold

93

93

Cost of receivables acquired (excluding
receivables related to sales)

(21,360)

(20,321)

1,395

1,448

(19,965)

(18,873)


 15

Acquisitions of businesses, net of cash acquired

(66)

(66)

Purchases of marketable securities

(4)

(3)

(126)

(137)

(130)

(140)

Purchases of property and equipment

(816)

(1,118)

(4)

(2)

(820)

(1,120)

Cost of equipment on operating leases acquired

(2,666)

(3,246)

830

917

(1,836)

(2,329)


 16

Increase in investment in Financial Services

(21)

(8)

21

8


 14

Decrease (increase) in trade and wholesale
receivables

1,999

(935)

(1,999)

935


 15

Collateral on derivatives – net

(6)

274

59

268

59

Other

(78)

35

(38)

(54)

89

(38)

(27)

(57)


 18

Net cash used for investing activities

(991)

(989)

(1,216)

(4,721)

(1,112)

1,786

(3,319)

(3,924)


Cash Flows from Financing Activities

Decrease in total short-term borrowings

(177)

(149)

(1,183)

(768)

(1,360)

(917)

Change in intercompany receivables/payables

(3,207)

(305)

3,207

305

Proceeds from long-term borrowings

4,586

1,348

4,685

8,638

9,271

9,986

Payments of long-term borrowings

(607)

(972)

(6,776)

(5,454)

(7,383)

(6,426)

Proceeds from issuance of common stock

331

178

331

178

Repurchases of common stock

(750)

(1,253)

(750)

(1,253)

Capital investment from Equipment Operations

21

8

(21)

(8)


 14

Dividends paid

(956)

(943)

(386)

(427)

386

427

(956)

(943)


 14

Other

(105)

(79)

(28)

(38)

1

(133)

(116)

Net cash provided by (used for) financing
activities

(885)

(2,175)

(460)

2,264

365

420

(980)

509


Effect of Exchange Rate Changes on Cash,
Cash Equivalents, and Restricted Cash

76

(42)

(44)

(14)

32

(56)


Net Increase (Decrease) in Cash, Cash
Equivalents, and Restricted Cash

2,960

(6)

256

(53)

3,216

(59)


Cash, Cash Equivalents, and Restricted Cash
at Beginning of Year

3,196

3,202

760

813

3,956

4,015


Cash, Cash Equivalents, and Restricted Cash
at End of Year

$

6,156

$

3,196

$

1,016

$

760

$

7,172

$

3,956

The supplemental consolidating data is presented for informational purposes. Transactions between the “Equipment Operations” and “Financial Services” have been eliminated to arrive at the consolidated financial statements.


1  The Equipment Operations represents the enterprise without Financial Services. The Equipment Operations includes the Company’s agriculture and turf operations, construction and forestry operations, and other corporate assets, liabilities, revenues and expenses not reflected within Financial Services.


12 Elimination of depreciation on leases related to inventory transferred to equipment on operating leases.


13 Reclassification of share-based compensation expense.


14 Elimination of dividends from Financial Services to the Equipment Operations, which are included in the Equipment Operations net cash provided by operating activities, and capital investments in Financial Services from the Equipment Operations.


15 Primarily reclassification of receivables related to the sale of equipment.


16 Reclassification of lease agreements with direct customers.


17 Reclassification of sales incentive accruals on receivables sold to Financial Services.


18 Elimination and reclassification of the effects of Financial Services partial financing of the construction and forestry retail locations sales and subsequent collection of those amounts.

 

 


Deere & Company


Other Financial Information

For the Twelve Months Ended

Equipment Operations*

Agriculture and Turf

Construction and Forestry*

November 1

November 3

November 1

November 3

November 1

November 3

Dollars in millions

2020

2019

2020

2019

2020

2019

Net Sales

$

31,272

$

34,886

$

22,325

$

23,666

$

8,947

$

11,220

Net Sales – excluding Roadbuilding

$

28,348

$

31,693

$

22,325

$

23,666

$

6,023

$

8,027

Average Identifiable Assets

With Inventories at LIFO

$

19,567

$

20,761

$

10,305

$

10,748

$

9,262

$

10,013

With Inventories at LIFO – excluding Roadbuilding

$

13,629

$

14,460

$

10,305

$

10,748

$

3,324

$

3,712

With Inventories at Standard Cost

$

20,984

$

22,139

$

11,455

$

11,860

$

9,529

$

10,279

With Inventories at Standard Cost –
excluding Roadbuilding

$

15,046

$

15,838

$

11,455

$

11,860

$

3,591

$

3,978

Operating Profit

$

3,559

$

3,721

$

2,969

$

2,506

$

590

$

1,215

Operating Profit – excluding Roadbuilding

$

3,289

$

3,378

$

2,969

$

2,506

$

320

$

872

Percent of Net Sales – excluding Roadbuilding

11.6

%

10.7

%

13.3

%

10.6

%

5.3

%

10.9

%

Operating Return on Assets – excluding Roadbuilding

With Inventories at LIFO – excluding Roadbuilding

24.1

%

23.4

%

28.8

%

23.3

%

9.6

%

23.5

%

With Inventories at Standard Cost –
excluding Roadbuilding

21.9

%

21.3

%

25.9

%

21.1

%

8.9

%

21.9

%

SVA Cost of Assets – excluding Roadbuilding

$

(1,806)

$

(1,900)

$

(1,375)

$

(1,423)

$

(431)

$

(477)

SVA – excluding Roadbuilding

$

1,483

$

1,478

$

1,594

$

1,083

$

(111)

$

395

For the Twelve Months Ended

Financial Services

November 1

November 3

Dollars in millions

2020

2019

Net Income Attributable to Deere & Company

$

566

$

539

Average Equity

$

5,099

$

5,040

Return on Equity

11.1

%

10.7

%

Operating Profit

$

746

$

694

Cost of Equity

$

(673)

$

(657)

SVA

$

73

$

37

 

The Company evaluates its business results on the basis of accounting principles generally accepted in the United States. In addition, it uses a metric referred to as Shareholder Value Added (SVA), which management believes is an appropriate measure for the performance of its businesses. SVA is, in effect, the pretax profit left over after subtracting the cost of enterprise capital. The Company is aiming for a sustained creation of SVA and is using this metric for various performance goals. Certain compensation is also determined on the basis of performance using this measure. For purposes of determining SVA, each of the equipment segments is assessed a pretax cost of assets, which on an annual basis is approximately 12 percent of the segment’s average identifiable operating assets during the applicable period with inventory at standard cost. Management believes that valuing inventories at standard cost more closely approximates the current cost of inventory and the Company’s investment in the asset. The Financial Services segment is assessed an annual pretax cost of approximately 13 percent of the segment’s average equity. The cost of assets or equity, as applicable, is deducted from the operating profit or added to the operating loss of each segment to determine the amount of SVA.

 

* The results and assets related to the Company’s Roadbuilding product line are excluded from the calculation of SVA to allow time for integration and assimilation of the 2017 acquisition of Wirtgen Group Holding GmbH’s operations.

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/deere-reports-net-income-of-757-million-for-fourth-quarter-2-751-billion-for-year-301180278.html

SOURCE Deere & Company

AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.

First, AIM reports that Roswell Park Comprehensive Cancer Center’s Phase 1/2a study evaluating the two-drug combination of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 is fully underway, with the first patient enrolled and treated on the study.

AIM is a collaborator on that clinical trial, which is funded in part through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park. AIM is providing Ampligen at no charge for this study. Full details about this trial, which is led by Roswell Park co-Principal Investigators, Drs. Brahm Segal and Pawel Kalinski, are available at ClinicalTrials.gov.

Additionally, the AIM team is working to develop:

  • An intranasal prophylaxis strategy for frontline workers, the elderly and other high-risk patients, including those with co-morbidities such as cancer; and
  • An effective therapy for COVID-19 Long Haulers, so named due to the persistence of their symptoms after their infections have ended.

According to AIM CEO Thomas K. Equels: “While major global pharmaceutical companies have largely focused their efforts on the critical need for a COVID-19 vaccine – with Moderna and Pfizer recently announcing significant and hopeful results – AIM believes there is an equally critical health need to develop an early-onset treatment for people already infected with the disease. We greatly appreciate the leadership of Dr. Brahm Segal and Dr. Pawel Kalinski, as well as the tremendous efforts of the entire team at Roswell Park. We look forward to providing further updates as this critical trial progresses.”

About AIM ImmunoTech Inc
.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. Any forward-looking statements set forth in this press release speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. For instance, no assurance can be given as to whether the above mentioned study will prove successful. No assurance can be given as to whether current or planned immuno-oncology clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if such clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Some of the world’s largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that the Company’s actions toward proving this will be given first priority or that another treatment that eventually proves capable will not make its efforts ultimately unproductive. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: [email protected]
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: [email protected]



Amazon Launches IP Accelerator in Europe to Help Small Businesses Protect Their Brands and Tackle Counterfeit

Amazon Launches IP Accelerator in Europe to Help Small Businesses Protect Their Brands and Tackle Counterfeit

IP Accelerator connects businesses with a network of trusted IP law firms who will charge pre-negotiated fees

Participating small businesses can access Amazon’s brand protection tools months before their trademark registration is issued

SEATTLE–(BUSINESS WIRE)–
Today, Amazon (NASDAQ: AMZN) launched Intellectual Property Accelerator (IP Accelerator) in France, Germany, Italy, Spain, Netherlands and the United Kingdom, making it easier and more cost effective for small and medium-sized businesses (SMBs) to obtain trademarks, protect their brands and tackle counterfeit goods.

IP Accelerator, which is available to any brand selling in Amazon’s stores, connects entrepreneurs directly with a curated network of European law firms with expertise in IP rights. Participating law firms will charge fees to SMBs at competitive, pre-negotiated rates, giving sellers confidence and clarity about how much obtaining a trademark will cost them. In addition, SMBs can also seek general IP advice from these law firms as their brands and businesses grow.

Amazon launched IP Accelerator specifically with small business owners in mind. Larger businesses are four times more likely than SMBs to register their Intellectual Property (IP) rights1. The main reason small business entrepreneurs do not protect their rights is because of a lack of knowledge about IP and not knowing where to turn2. The process can be complicated, particularly for entrepreneurs in the early stages of setting up a business, and Amazon wanted to provide low cost assistance to all European SMBs, including the over 150,000 European-based SMBs selling on Amazon. Selling partners continue to account for more than 50% of products Amazon sells in its online stores.

IP rights are vital for businesses wanting to stop unauthorized parties from using their brands or copying their ideas. Owning IP can also create new sources of revenue should entrepreneurs wish to license their goods or services to third parties.

Businesses using IP Accelerator will also get access to Amazon’s wider brand protection services months or even years before their trademark registration is officially issued. Amazon’s Brand Registry provides SMBs with powerful tools that help them manage and protect their brand and IP rights in Amazon stores. Brand Registry is a free service and more than 350,000 brands are already enrolled. Participants benefit from Amazon’s automated protections that use information about brands to proactively remove suspected infringing or inaccurate content. Brands are also able to find and report suspected infringement through more powerful tools and can gain greater influence over product information displayed on Amazon’s product detail pages so customers can make confident, informed purchasing decisions on Amazon.

Francois Saugier, Vice President for EU Seller Services, Amazon,said: “We know from our conversations with small business owners that there is often confusion about why IP rights are important and how sellers can secure them. As part of our broader commitment to supporting small businesses, we have set up IP Accelerator to make the IP registration process as easy and as affordable as possible for entrepreneurs in the early days of their businesses.”

Pippa Hall, Director of Innovation and Chief Economist, from the UK’s Intellectual Property Office, said: “Great ideas are the core of every good business. Turning those ideas into a reality relies on IP. Understanding, protecting and getting the most out of your IP is a crucial ingredient of success. A good IP strategy should sit at the heart of every good business plan.”

Amazon has selected participating IP law firms based on their experience, expertise, and customer service. They will support SMBs with all aspects of the trademark filing process, such as researching a brand to see if anyone else is already using it and providing tailored advice on trademark applications. Over one hundred trademark experts across Europe have signed up to the program.

Tilman Vossius, of Barkhoff, Reimann Vossius, Germany, said:“The IP Accelerator Programme is the first worldwide programme to provide rapid trademarking registration for small and medium-sized businesses. Amazon has helped SMBs by selecting respected IP firms across Europe and negotiating extremely good prices for them.”

José Ignacio San Martín, Associate Partner, Elzaburu, Spain, said: “The trademark is probably the most important intangible asset for a company. It allows a company’s products to be identified and differentiated from those of the competition. Amazon’s IP Accelerator is to be welcomed because it will mean more businesses will register their trademarks and also allows them to access all the benefits of Amazon’s Brand Registry.”

Julius Stobbs, Founder, Stobbs IP, UK, said: “We are excited to be involved in this programme. It is great that Amazon is placing such an emphasis on IP protection and respecting the rights of brand owners. IP Accelerator elevates the importance of IP and pushes smaller companies to do the right thing: obtaining and respecting IP rights.”

IP Accelerator was launched in the United States in 2019. Since the launch, Amazon has connected SMBs with participating IP law firms, resulting in 6,000 trademark applications submitted to the US Patent and Trademark Office.

Dewar Gaines, Owner and Operator of premium pet products business Gaines Family Farmstead, used IP Accelerator in 2019 to register his trademark, and can testify how European small firms can also benefit from the programme. Mr Gaines said: “As with any quickly growing business, there is always risk of people copying or stealing your hard work and capitalizing on your growth. As a result of filing our trademark through IP Accelerator, I am more confident than ever that our brand is secure, leaving me and my team more time to concentrate on providing awesome products to our incredible customers.”

Amazon does not charge businesses to use IP Accelerator – SMBs only pay their law firm directly for the work performed at pre-negotiated rates. Businesses interested in IP Accelerator can go to: http://brandservices.amazon.com/ipaccelerator. Law firms that are interested in participating in the program should contact [email protected]

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

1 According to research conducted by the EUIPO, 9% of EU SMBs have registered IP rights compared to 36% of larger companies. https://www.clustercollaboration.eu/sites/default/files/news_attachment/roadmap_-_intellectual_property_action_plan.pdf

2 38% of respondents to a recent study (IP SME scorecard, EUIPO 2019) reported a lack of knowledge about IP as the main reason for not seeking registration. Research cited in https://www.clustercollaboration.eu/sites/default/files/news_attachment/roadmap_-_intellectual_property_action_plan.pdf

Amazon.com, Inc.

Media Hotline

[email protected]

www.amazon.com/pr

KEYWORDS: Washington Netherlands Germany North America Europe United States Spain France United Kingdom

INDUSTRY KEYWORDS: Professional Services Entertainment Other Entertainment Small Business Technology Legal Other Technology

MEDIA:

Logo
Logo

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 56 / 2020

Copenhagen, November 25, 2020 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078) has received information on transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Zealand Pharma’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand Pharma markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand Pharma-invented peptide therapeutics.

Zealand Pharma was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.  

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: [email protected]

For U.S. Media

David Rosen
Argot Partners
Phone: 212-600-1902
Email: [email protected]

Attachments



Amesite Inc. Announces Appointment of George Parmer to its Board of Directors

PR Newswire

ANN ARBOR, Mich., Nov. 25, 2020 /PRNewswire/ — AmesiteInc. (Nasdaq: AMST), an artificial intelligence software company providing online learning ecosystems for business, higher education, and K-12, announced today that global investor, developer and entrepreneur George Parmer has joined its Board of Directors. The appointment brings the total number of board members to seven.

“George is an extremely successful entrepreneur with deep expertise in investing and public and private ventures,” said Amesite Founder and CEO Dr. Ann Marie Sastry. “He is a visionary that anticipated trends in living – and building – well before the pandemic hit and has been successfully executing on expansion plans that are proving to be incredibly timely. His acumen in business is paired with a wisdom that comes from decades of building businesses brick-by-brick. We are so proud to have him on our Board of Directors.”

Parmer sits on the board of Linkbancorp, Inc., is the Chairman of the Board of Trustees at Messiah University in Pennsylvania. He is the founder and president of residential home building and development company Fine Line Homes, which has developments along the east coast from New York to North Carolina. He is also the founder and president of nationwide company Residential Warranty Corporation and three insurance companies located in Colorado, Pennsylvania, and Texas.

“Accessible, affordable and engaging remote learning and training solutions are so important right now and I’m excited to be on the board of a company that is leading the way in delivering the necessary solutions to the education and business sectors,” Parmer said. “As both a business owner and an educational trustee, I’ve seen firsthand what is needed if we are going to make up the millions of learning hours lost to the pandemic and I’m ready to get to work to bring my decades of experience to the table as Amesite grows.”


About Amesite Inc.

Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for K-12, college, university and business education and upskilling. Amesite-offered courses and programs are branded to our customers.  Amesite uses artificial intelligence technologies to provide customized environments for learners, easy-to-manage interfaces for instructors, and greater accessibility for learners in the US education market and beyond.  The Company leverages existing institutional infrastructures, adding mass customization and cutting-edge technology to provide cost-effective, scalable and engaging experiences for learners anywhere. For more information, visit https://amesite.com.


Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company’s planned online machine learning platform, the Company’s business plans, any future commercialization of the Company’s online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact: Robert Busweiler[email protected] – 631.379.6454

Cision View original content:http://www.prnewswire.com/news-releases/amesite-inc-announces-appointment-of-george-parmer-to-its-board-of-directors-301180240.html

SOURCE Amesite Inc.

IRD Awarded Virtual Weigh Station (VWS) System in Oklahoma

PR Newswire


  • Contract expands IRD’s VWS Solution in the North American Commercial Vehicle Enforcement Market

SASKATOON, SK, Nov. 25, 2020 /PRNewswire/ – International Road Dynamics Inc. (“IRD”), a Quarterhill Inc. (“Quarterhill”) company (TSX: QTRH) (OTCQX: QTRH), announced today that the Oklahoma Department of Transportation (ODOT) has authorized IRD to move forward with the installation of a VWS System. The financial terms of the contract are confidential.

The VWS System includes two lanes that will be instrumented with IRD’s turnkey Weigh-In-Motion (WIM) Systems. The project is expected to commence in the first quarter of 2021, and once implemented, IRD will maintain the system for a five-year period.

Mr. Rish Malhotra, IRD’s President and CEO commented: “Our VWS System is a leader in generating transportation intelligence. It enables the collection of real-time traffic data which can be used for the enforcement of overweight vehicles and to enhance overall road safety. This project builds on the previous deployments of four Port-of-Entry Electronic Screening Systems in Oklahoma and we are pleased to expand our relationship with the ODOT.”

IRD’s turnkey WIM Systems are integrated with Automated License Plate Readers, Automated USDOT Number Readers , and Vehicle Overview Cameras.  These systems will be used to detect and screen commercial vehicles, in real-time, for size, weight, and safety. IRD’s System uses an Intelligent Roadside Operations Computer (iROC) for Electronic Screening and interfaces with Oklahoma’s State Commercial Vehicle Information Exchange Window (CVIEW) and Federal Motor Carrier Safety Administration (FMCSA) Safety and Fitness Electronic Records (SAFER). This inter-connectivity provides better data collection to identify potential violators, focus on safety initiatives, improve road design and protection of Oklahoma’s single largest asset, its highway infrastructure.

About IRD
IRD is a dynamic technology company engaged in developing key components and advanced systems for the next generation of transportation networks. Together with subsidiaries PAT Traffic and ICOMS Detections, IRD supplies Intelligent Transportation Systems (ITS) to private corporations, transportation agencies, and highway authorities around the world. IRD’s systems make highways safer, greener, and more efficient. Known globally as a trusted partner providing sales, service, and installation support on major ITS projects for over 40 years, IRD contributes to creating smarter cities by empowering engineering and urban planning professionals to access reliable traffic data. For more information: www.irdinc.com

About Quarterhill
Quarterhill is a growth-oriented company in the Intellectual Property and Intelligent Transportation System (ITS) industries. Our goal is to pursue an investment strategy that capitalizes on attractive market trends in both ITS and its adjacent markets. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. For more information: www.quarterhill.com

Forward-Looking Information
This news release contains forward-looking statements regarding IRD, Quarterhill and their businesses. Forward-looking statements are based on estimates and assumptions made by IRD and/or Quarterhill in light of their experience and perception of historical trends, current conditions, expected future developments and the expected effects of new business strategies, as well as other factors that IRD and/or Quarterhill believe are appropriate in the circumstances. The forward-looking events and circumstances discussed herein may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting IRD and/or Quarterhill, including: potential risks and uncertainties relating to the ultimate geographic spread of the novel coronavirus (“COVID-19”); the severity of the disease; the duration of the COVID-19 outbreak; actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact; the potential negative impacts of COVID-19 on the global economy and financial markets and any resulting impact on IRD and/or Quarterhill and/or their businesses. Other factors include, without limitation, the risks described in Quarterhill’s February 27, 2020 annual information form for the year ended December 31, 2019 (the “AIF”). Copies of the AIF may be obtained at www.sedar.com. IRD and Quarterhill recommend that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of IRD’s forward-looking statements. IRD has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Cision View original content:http://www.prnewswire.com/news-releases/ird-awarded-virtual-weigh-station-vws-system-in-oklahoma-301180176.html

SOURCE International Road Dynamics